Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis
Aims: To determine the prognostic significance of β‐catenin in aggressive fibromatosis and to identify potential molecular markers for new targeted therapies. Methods and results: A tissue microarray of 37 cases of deep aggressive fibromatosis was constructed and subjected to immunohistochemical a...
Gespeichert in:
| Veröffentlicht in: | Histopathology 2007-03, Vol.50 (4), p.491-497 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 497 |
|---|---|
| container_issue | 4 |
| container_start_page | 491 |
| container_title | Histopathology |
| container_volume | 50 |
| creator | Gebert, C Hardes, J Kersting, C August, C Supper, H Winkelmann, W Buerger, H Gosheger, G |
| description | Aims: To determine the prognostic significance of β‐catenin in aggressive fibromatosis and to identify potential molecular markers for new targeted therapies.
Methods and results: A tissue microarray of 37 cases of deep aggressive fibromatosis was constructed and subjected to immunohistochemical analysis for β‐catenin, p53, smooth muscle actin (SMA), desmin, Ki67, c‐erbB2, epidermal growth factor receptor (EGFR), c‐kit, CD34 and S100. Complete clinical follow‐up was available for 23 patients. Nuclear β‐catenin expression was associated with an increased rate of local tumour recurrence (60.0% 1‐year and 0% 5‐year event‐free survival; P |
| doi_str_mv | 10.1111/j.1365-2559.2007.02619.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70409724</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70409724</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4359-47bfcb4fcd90d8ca5646caf86f457eba63dc52a2c69c14bcf4ca4bf9ee2e6e9d3</originalsourceid><addsrcrecordid>eNqNkM9u0zAcgC0EYmXwCsgXuCVzHP-JDxxgGu2kahw2qMTFcpyfK5c0DnY6utfiQfZMS9Zqu84XW_L32T99COGC5MW4zjZ5UQqeUc5VTgmROaGiUPn-FZo9XbxGM1ISlZFCyBP0LqUNIYUsKX2LTgrJWEUon6HVxb6PkJIPHQ4O3__PrBmg8x02XYN7XmITAfcxrLuQBm-xM3YIMeGRaAB6bNbrR_8WsPN1DFszhOTTe_TGmTbBh-N-in5-v7g5X2TLH_PL86_LzLKSq4zJ2tmaOdso0lTWcMGENa4SjnEJtRFlYzk11AplC1Zbx6xhtVMAFASopjxFnw_vjiP-3UEa9NYnC21rOgi7pCVhREnKRrA6gDaGlCI43Ue_NfFOF0RPUfVGT-301E5PUfVjVL0f1Y_HP3b1Fppn8VhxBD4dAZOsaV00nfXpmau4VJTQkfty4P75Fu5ePIBeXF5Pp9HPDr5PA-yffBP_aCFLyfXqaq5_y283v5bzhV6VD11upHU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70409724</pqid></control><display><type>article</type><title>Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Gebert, C ; Hardes, J ; Kersting, C ; August, C ; Supper, H ; Winkelmann, W ; Buerger, H ; Gosheger, G</creator><creatorcontrib>Gebert, C ; Hardes, J ; Kersting, C ; August, C ; Supper, H ; Winkelmann, W ; Buerger, H ; Gosheger, G</creatorcontrib><description>Aims: To determine the prognostic significance of β‐catenin in aggressive fibromatosis and to identify potential molecular markers for new targeted therapies.
Methods and results: A tissue microarray of 37 cases of deep aggressive fibromatosis was constructed and subjected to immunohistochemical analysis for β‐catenin, p53, smooth muscle actin (SMA), desmin, Ki67, c‐erbB2, epidermal growth factor receptor (EGFR), c‐kit, CD34 and S100. Complete clinical follow‐up was available for 23 patients. Nuclear β‐catenin expression was associated with an increased rate of local tumour recurrence (60.0% 1‐year and 0% 5‐year event‐free survival; P < 0.05). Furthermore, p53 expression was associated with an increased risk of tumour recurrence (50% 1‐year event‐free survival rate and 0% 5‐years event‐free survival rate, P < 0.05). The coexpression of p53 and β‐catenin was significantly correlated (P < 0.05). No statistically significant association was seen between MIB1 and p53 or β‐catenin expression, respectively. No expression of EGFR, c‐erbB2 or c‐kit was seen.
Conclusions: The overexpression of β‐catenin and p53 is associated with a decreased event‐free survival in deep aggressive fibromatosis. Further studies are required to establish whether these findings can lead to an improvement in the treatment of this rare neoplasm.</description><identifier>ISSN: 0309-0167</identifier><identifier>EISSN: 1365-2559</identifier><identifier>DOI: 10.1111/j.1365-2559.2007.02619.x</identifier><identifier>PMID: 17448025</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; beta Catenin - biosynthesis ; Biological and medical sciences ; Child ; Child, Preschool ; fibromatosis ; Fibromatosis, Aggressive - diagnosis ; Fibromatosis, Aggressive - metabolism ; Humans ; Infant ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; Middle Aged ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Prognosis ; Tissue Array Analysis ; Tumor Suppressor Protein p53 - biosynthesis ; β-catenin</subject><ispartof>Histopathology, 2007-03, Vol.50 (4), p.491-497</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4359-47bfcb4fcd90d8ca5646caf86f457eba63dc52a2c69c14bcf4ca4bf9ee2e6e9d3</citedby><cites>FETCH-LOGICAL-c4359-47bfcb4fcd90d8ca5646caf86f457eba63dc52a2c69c14bcf4ca4bf9ee2e6e9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2559.2007.02619.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2559.2007.02619.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>313,314,780,784,792,1417,27922,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18579202$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17448025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gebert, C</creatorcontrib><creatorcontrib>Hardes, J</creatorcontrib><creatorcontrib>Kersting, C</creatorcontrib><creatorcontrib>August, C</creatorcontrib><creatorcontrib>Supper, H</creatorcontrib><creatorcontrib>Winkelmann, W</creatorcontrib><creatorcontrib>Buerger, H</creatorcontrib><creatorcontrib>Gosheger, G</creatorcontrib><title>Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis</title><title>Histopathology</title><addtitle>Histopathology</addtitle><description>Aims: To determine the prognostic significance of β‐catenin in aggressive fibromatosis and to identify potential molecular markers for new targeted therapies.
Methods and results: A tissue microarray of 37 cases of deep aggressive fibromatosis was constructed and subjected to immunohistochemical analysis for β‐catenin, p53, smooth muscle actin (SMA), desmin, Ki67, c‐erbB2, epidermal growth factor receptor (EGFR), c‐kit, CD34 and S100. Complete clinical follow‐up was available for 23 patients. Nuclear β‐catenin expression was associated with an increased rate of local tumour recurrence (60.0% 1‐year and 0% 5‐year event‐free survival; P < 0.05). Furthermore, p53 expression was associated with an increased risk of tumour recurrence (50% 1‐year event‐free survival rate and 0% 5‐years event‐free survival rate, P < 0.05). The coexpression of p53 and β‐catenin was significantly correlated (P < 0.05). No statistically significant association was seen between MIB1 and p53 or β‐catenin expression, respectively. No expression of EGFR, c‐erbB2 or c‐kit was seen.
Conclusions: The overexpression of β‐catenin and p53 is associated with a decreased event‐free survival in deep aggressive fibromatosis. Further studies are required to establish whether these findings can lead to an improvement in the treatment of this rare neoplasm.</description><subject>Adolescent</subject><subject>Adult</subject><subject>beta Catenin - biosynthesis</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>fibromatosis</subject><subject>Fibromatosis, Aggressive - diagnosis</subject><subject>Fibromatosis, Aggressive - metabolism</subject><subject>Humans</subject><subject>Infant</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Prognosis</subject><subject>Tissue Array Analysis</subject><subject>Tumor Suppressor Protein p53 - biosynthesis</subject><subject>β-catenin</subject><issn>0309-0167</issn><issn>1365-2559</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM9u0zAcgC0EYmXwCsgXuCVzHP-JDxxgGu2kahw2qMTFcpyfK5c0DnY6utfiQfZMS9Zqu84XW_L32T99COGC5MW4zjZ5UQqeUc5VTgmROaGiUPn-FZo9XbxGM1ISlZFCyBP0LqUNIYUsKX2LTgrJWEUon6HVxb6PkJIPHQ4O3__PrBmg8x02XYN7XmITAfcxrLuQBm-xM3YIMeGRaAB6bNbrR_8WsPN1DFszhOTTe_TGmTbBh-N-in5-v7g5X2TLH_PL86_LzLKSq4zJ2tmaOdso0lTWcMGENa4SjnEJtRFlYzk11AplC1Zbx6xhtVMAFASopjxFnw_vjiP-3UEa9NYnC21rOgi7pCVhREnKRrA6gDaGlCI43Ue_NfFOF0RPUfVGT-301E5PUfVjVL0f1Y_HP3b1Fppn8VhxBD4dAZOsaV00nfXpmau4VJTQkfty4P75Fu5ePIBeXF5Pp9HPDr5PA-yffBP_aCFLyfXqaq5_y283v5bzhV6VD11upHU</recordid><startdate>200703</startdate><enddate>200703</enddate><creator>Gebert, C</creator><creator>Hardes, J</creator><creator>Kersting, C</creator><creator>August, C</creator><creator>Supper, H</creator><creator>Winkelmann, W</creator><creator>Buerger, H</creator><creator>Gosheger, G</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200703</creationdate><title>Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis</title><author>Gebert, C ; Hardes, J ; Kersting, C ; August, C ; Supper, H ; Winkelmann, W ; Buerger, H ; Gosheger, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4359-47bfcb4fcd90d8ca5646caf86f457eba63dc52a2c69c14bcf4ca4bf9ee2e6e9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>beta Catenin - biosynthesis</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>fibromatosis</topic><topic>Fibromatosis, Aggressive - diagnosis</topic><topic>Fibromatosis, Aggressive - metabolism</topic><topic>Humans</topic><topic>Infant</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Prognosis</topic><topic>Tissue Array Analysis</topic><topic>Tumor Suppressor Protein p53 - biosynthesis</topic><topic>β-catenin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gebert, C</creatorcontrib><creatorcontrib>Hardes, J</creatorcontrib><creatorcontrib>Kersting, C</creatorcontrib><creatorcontrib>August, C</creatorcontrib><creatorcontrib>Supper, H</creatorcontrib><creatorcontrib>Winkelmann, W</creatorcontrib><creatorcontrib>Buerger, H</creatorcontrib><creatorcontrib>Gosheger, G</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Histopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gebert, C</au><au>Hardes, J</au><au>Kersting, C</au><au>August, C</au><au>Supper, H</au><au>Winkelmann, W</au><au>Buerger, H</au><au>Gosheger, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis</atitle><jtitle>Histopathology</jtitle><addtitle>Histopathology</addtitle><date>2007-03</date><risdate>2007</risdate><volume>50</volume><issue>4</issue><spage>491</spage><epage>497</epage><pages>491-497</pages><issn>0309-0167</issn><eissn>1365-2559</eissn><abstract>Aims: To determine the prognostic significance of β‐catenin in aggressive fibromatosis and to identify potential molecular markers for new targeted therapies.
Methods and results: A tissue microarray of 37 cases of deep aggressive fibromatosis was constructed and subjected to immunohistochemical analysis for β‐catenin, p53, smooth muscle actin (SMA), desmin, Ki67, c‐erbB2, epidermal growth factor receptor (EGFR), c‐kit, CD34 and S100. Complete clinical follow‐up was available for 23 patients. Nuclear β‐catenin expression was associated with an increased rate of local tumour recurrence (60.0% 1‐year and 0% 5‐year event‐free survival; P < 0.05). Furthermore, p53 expression was associated with an increased risk of tumour recurrence (50% 1‐year event‐free survival rate and 0% 5‐years event‐free survival rate, P < 0.05). The coexpression of p53 and β‐catenin was significantly correlated (P < 0.05). No statistically significant association was seen between MIB1 and p53 or β‐catenin expression, respectively. No expression of EGFR, c‐erbB2 or c‐kit was seen.
Conclusions: The overexpression of β‐catenin and p53 is associated with a decreased event‐free survival in deep aggressive fibromatosis. Further studies are required to establish whether these findings can lead to an improvement in the treatment of this rare neoplasm.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17448025</pmid><doi>10.1111/j.1365-2559.2007.02619.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0309-0167 |
| ispartof | Histopathology, 2007-03, Vol.50 (4), p.491-497 |
| issn | 0309-0167 1365-2559 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70409724 |
| source | MEDLINE; Wiley Journals |
| subjects | Adolescent Adult beta Catenin - biosynthesis Biological and medical sciences Child Child, Preschool fibromatosis Fibromatosis, Aggressive - diagnosis Fibromatosis, Aggressive - metabolism Humans Infant Investigative techniques, diagnostic techniques (general aspects) Medical sciences Middle Aged Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Prognosis Tissue Array Analysis Tumor Suppressor Protein p53 - biosynthesis β-catenin |
| title | Expression of β-catenin and p53 are prognostic factors in deep aggressive fibromatosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A19%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20%CE%B2-catenin%20and%20p53%20are%20prognostic%20factors%20in%20deep%20aggressive%20fibromatosis&rft.jtitle=Histopathology&rft.au=Gebert,%20C&rft.date=2007-03&rft.volume=50&rft.issue=4&rft.spage=491&rft.epage=497&rft.pages=491-497&rft.issn=0309-0167&rft.eissn=1365-2559&rft_id=info:doi/10.1111/j.1365-2559.2007.02619.x&rft_dat=%3Cproquest_cross%3E70409724%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70409724&rft_id=info:pmid/17448025&rfr_iscdi=true |